Recurrent Melanoma Completed Phase 2 Trials for Saracatinib (DB11805)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00669019Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By SurgeryTreatment